Literature DB >> 12545035

Long-term cost effectiveness of drotrecogin alfa (activated): an unanswered question.

Steven M Banks, Eric Gerstenberger, Peter Q Eichacker, Charles Natanson.   

Abstract

Mesh：

Substances：

Year:  2003        PMID： 12545035     DOI： 10.1097/00003246-200301000-00050

Source DB:  PubMed          Journal:  Crit Care Med        ISSN： 0090-3493            Impact factor:   7.598


× No keyword cloud information.
  4 in total

1.  [Endogenous anticoagulant therapy for sepsis. Success and failure].

Authors:  C J Wiedermann
Journal:  Internist (Berl)       Date:  2007-05       Impact factor: 0.743

2.  An algorithmic computerised order entry approach to assist in the prescribing of new therapeutic agents: case study of activated protein C at an academic medical centre.

Authors:  Michael A Fischer; Craig M Lilly; William W Churchill; Lindsey R Baden; Jerry Avorn
Journal:  Drug Saf       Date:  2004       Impact factor: 5.606

Review 3.  Drotrecogin alfa (activated): a pharmacoeconomic review of its use in severe sepsis.

Authors:  James E Frampton; Rachel H Foster
Journal:  Pharmacoeconomics       Date:  2004       Impact factor: 4.981

Review 4.  Year in review 2007: Critical Care--multiple organ failure and sepsis.

Authors:  James M O'Brien; Naeem A Ali; Edward Abraham
Journal:  Crit Care       Date:  2008-10-14       Impact factor: 9.097
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.